This description, taken on September 9, 2020, shows a test tube labeled the vaccine in front of the Astrogeneca logo. Dado Ruvik | Reuters London – The corona virus vaccine, developed by British pharmaceutical company AstroGeneca in association with Oxford University, is the first to independently review its post-test results and publish it in the medical journal. Interim results The third phase of the trials of the Oxford-Astrogeneca vaccine was released Tuesday in Lancet. Peer-review is reviewed by other experts in the field before articles or studies are published, which serves as another quality control measure for innovation. The study reaffirmed the test results for the shared vaccine a few weeks ago, which showed that the average efficacy in protection against a corona virus was 70%. It is shown in two full dosages with two full doses showing 62% efficacy and 90% efficacy with semi-full-full dose terms. This is an important message, please check back later for more details. .
Source